Breaks Categories: News

TuesdayFeb 14, 2017 9:44 am

NetworkNewsBreaks – Data from CytoDyn’s (CYDY) Ongoing Phase 2b Extension Study of PRO 140 to be Presented at CROI 2017

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning announced that data from its ongoing Phase 2b extension study with PRO 140 as a monotherapy for the treatment of HIV-infected patients will be presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. The company’s data will be the subject of a poster presentation on February 15 before being featured in a Themed Discussion on February 16. Dr. Kush Dhody, Senior Director, Clinical Operations at Amarex Clinical Research, is scheduled to make the presentation and participate in the discussion on CytoDyn’s behalf. For those unable to attend the conference,…

Continue Reading

MondayFeb 13, 2017 10:49 am

NetworkNewsBreaks – Micronet (NASDAQ: MICT) Announces New Purchase Order for TREQ®-317

Micronet Enertec Technologies (NASDAQ: MICT) this morning said its Mobile Resource Management (MRM) subsidiary, Micronet Inc., has received a purchase order valued at approximately $800,000 from a leading American school bus fleet management solutions provider for the company’s all-in-one TREQ®-317. TREQ®-317 is an Android tablet designed to improve efficiency, manage the time and attendance of K-12 fleet drivers, improve vehicle maintenance by using the engine diagnostics and fault code alerts, optimize bus routes, and manage student ridership. The company expects to fulfill the order during the second quarter of 2017. "This marks Micronet's first order for our all-in-one TREQ®-317 product…

Continue Reading

MondayFeb 13, 2017 10:08 am

NetworkNewsBreaks – Zosano Pharma Corp.’s (NASDAQ: ZSAN) M207 Meets Co-primary Endpoints in Efficacy Trial; Shares Skyrocket

Shares of Zosano Pharma (NASDAQ: ZSAN) soared more than 100% this morning on news that the company’s lead product candidate, M207, achieved both co-primary endpoints in the recently completed ZOTRIP trial. The ZOTRIP pivotal efficacy study compared three doses (1.0mg, 1.9mg and 3.8mg) of M207, a novel transdermal therapeutic, to placebo for a single migraine attack. The 3.8mg dose achieved significance in the secondary endpoints of pain freedom at 45 minutes and one hour and showed durability of effect on pain freedom at 24 and 48 hours. Overall, higher pain freedom rates were achieved on all doses after 60 minutes…

Continue Reading

MondayFeb 13, 2017 9:20 am

NetworkNewsBreaks – ChineseInvestors.com (CIIX) Issues Update on Recent Financial and Business Achievements

ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning issued a news release highlighting some of its financial and business achievements for January 2017, as well as its plans to build on these milestones moving forward. After reporting significantly higher revenues for the three- and six-month periods ended November 30, 2016, the company has now achieved revenue growth for three consecutive quarters, and ChineseInvestors.com will look to continue this trend through its entry into the hemp-based cannabidiol (CBD) health products market. In addition to completing a $5 million private placement, the company kicked off 2017 with the launch of its new www.ChineseCBDoil.com site,…

Continue Reading

FridayFeb 10, 2017 12:39 pm

NetworkNewsBreaks – MediWound Ltd. (NASDAQ: MDWD) Still Inching Higher on Positive NexoBrid Results

Shares of MediWound (NASDAQ: MDWD) are ticking higher a day after the company reported positive results from its phase 2 study evaluating the safety, pharmacokinetics (transcutaneous absorption) and efficacy of NexoBrid in hospitalized children and adults with severe thermal burns. As a topically administered eschar removal agent, NexoBrid provides a much needed alternative to surgical excision. Surgery of large surfaces of eschar is often limited by the availability of the extensive donor site required. Additionally, surgical excision results in significant surgical burden on these very severe patients including immense blood loss. The phase 2 study included 36 patients with severe…

Continue Reading

ThursdayFeb 09, 2017 1:05 pm

NetworkNewsBreaks – Viking Therapeutics, Inc. (NASDAQ: VKTX) Shares Reverse from Early Rally on Positive Initial Data from VK2809 Study

Shares of Viking Therapeutics (NASDAQ: VKTX) are trading lower, pulling back from a pre-market surge of 10% after the company announced positive initial results from a proof-of-concept study of VK2809 for the treatment of GSD Ia, a rare orphan genetic disease. The data demonstrates that treatment with VK2809 led to statistically significant reductions in key metabolic markers of GSD Ia, including rapid and substantial reductions in liver triglyceride content, liver weight and liver weight as a percentage of body weight, as compared with vehicle-treated controls. "These initial proof-of-concept data showing VK2809's activity in this model of GSD Ia are very…

Continue Reading

ThursdayFeb 09, 2017 12:18 pm

NetworkNewsBreaks – MemReg, Inc. (MREG) Announces Changes to Name and Ticker Symbol

Cloud-based health care software-as-a-service company MemReg, Inc. (OTC: MREG) this morning announced its intention to change its name to ORHub, Inc. in an effort to better reflect its current business. The change, which has already received FINRA approval, also includes a change in ticker symbol to ORHB, effective February 10, 2017. CEO Colt Melby noted the importance of this change in this morning’s update. “Our official name change and new stock ticker symbol signifies the final step in the Company's transformation into a publicly traded software company focused on development and commercialization of productivity and information software for surgical operations,”…

Continue Reading

ThursdayFeb 09, 2017 9:59 am

NetworkNewsBreaks – eXp World Holdings, Inc. (EXPI) Hosting Webinar on February 23

eXp World Holdings, Inc. (OTCQB: EXPI), holding company for eXp Realty LLC, this morning announced its plans to host a corporate update webinar on Thursday, February 23, 2017, at 8:30 AM Pacific Time. The call, which is to be hosted by Glenn Sanford, chairman and CEO of EXPI, and Alan Goldman, the company’s CFO, will feature a look into EXPI’s sustained growth in the real estate sector, as well as an overview of the company’s unique business model and some insight into its key milestones. To access the call, interested investors should dial 1-888-221-3884 if within the United States or…

Continue Reading

WednesdayFeb 08, 2017 12:16 pm

NetworkNewsBreaks – Plug Power, Inc. (NASDAQ: PLUG) Ships First Production ProGen Engines to CA; Chinese Shipments Set For Q2 2017

Plug Power (NASDAQ: PLUG) this morning announced its shipment of the first production ProGen fuel cell engines for use in electric delivery vehicles. The first deliveries will function as range extenders in electric FedEx Freight delivery vans in and around Los Angeles, doubling the vehicle’s range. ProGen engine shipments for delivery vans in the China market begin in the second quarter of 2017 and will be utilized for on-road trials and certification. The company notes that China is actively driving fuel cell and hydrogen adoption within the country, making it an attractive market. “The electrification of the auto market is…

Continue Reading

TuesdayFeb 07, 2017 10:28 am

NetworkNewsBreaks – Stealth Technologies, Inc. (STTH) Announces Engagement of NetworkNewsWire

Stealth Technologies, Inc. (OTCQB: STTH), a company focused on the development and commercialization of technology aimed at identity protection and personal safety, this morning announced its engagement of NetworkNewsWire (NNW) for corporate communications solutions. NNW is a multifaceted financial news and publishing company working to help public and private organizations find their voice and build market visibility by leveraging a rapidly expanding distribution network of more than 5,000 key syndication outlets. “Innovation is a cornerstone of our corporate strategy at Stealth Technologies, and this includes constant refining of our communications initiatives as we capture our share of the personal emergency…

Continue Reading